- Biomerica announced the expansion of its CDMO services to meet growing demand from diagnostic and biotechnology companies.
- The company will provide end-to-end support from assay development to commercial manufacturing, underpinned by ISO 13485 and FDA cGMP compliance.
Biomerica, Inc. has expanded its Contract Development and Manufacturing Organization (CDMO) services to address rising demand from diagnostic and biotechnology firms. The company’s enhanced offering will support customers across the entire product development lifecycle, from concept through to commercial manufacturing.
The expanded portfolio covers assay development, antibody and reagent services, recombinant antibody development, manufacturing and assembly, and technology transfer support. These services encompass a range of diagnostic products, including lateral flow, point-of-care, ELISA, and Multiplex ELISA assays.
“Over the past several years, we have experienced a meaningful increase in interest from both large diagnostic to smaller innovative organisations who are seeking to leverage our specialised development expertise, regulatory compliance track record, and manufacturing capabilities. We are now formalising and expanding these CDMO services, providing clients with end-to-end support from concept through commercial manufacturing.”
Zack Irani, Chief Executive Officer of Biomerica
Biomerica’s CDMO operations are supported by ISO 13485 certification, CE-mark expertise, and an FDA-registered cGMP manufacturing facility. The company also updated its corporate website to help potential partners access detailed information about its expanded service offerings.
